Rameda acquires leading anti-diabetic product
Updated 9/30/2024 9:40:00 AM
Arab Finance: Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) has completed its largest acquisition to date, securing a top-selling anti-diabetic product used to treat type 2 diabetes, as per a disclosure.
The newly acquired product leads the newer-generation oral anti-diabetics market with a 9% share, in a segment valued at over EGP 6.7 billion.
According to IQVIA, the market has seen impressive growth with a three-year compound annual growth rate (CAGR) of 43% in value and 22% in units sold.
The product itself has outperformed the market, recording a 60% CAGR in value and 42% in units sold over the past three years.
Available in four concentrations, the product’s average price of around EGP 130 is higher than Rameda's average selling price, further boosting the company’s profit margins.
With this acquisition, the product is expected to be among Rameda's top three contributors, generating over EGP 400 million in sales by 2025.
Related News
